{"prompt": "['account the unique needs of each patient.', 'If myasthenia gravis-like neurotoxicity is present, consider', 'starting AChE inhibitor therapy in addition to steroids. Such', 'therapy, if successful, can also serve to reinforce the', 'diagnosis.', 'GUILLAIN-BARRE:', 'It is important to consider here that the use of steroids as the', 'primary treatment of Guillain-Barre is not typically', 'considered effective.', 'Patients requiring treatment should be started with IV IG and', 'followed by plasmapheresis if not responsive to IV IG.', 'Grade 3 or 4', 'For Grade 3:', 'For Grade 3 or 4 (severe or life-threatening events):', '-', 'Hold study drug/study regimen dose until', 'Consider, as necessary, discussing with study physician.', '-', 'resolution to Grade 1.', 'Recommend hospitalization.', '-', 'Monitor symptoms and obtain neurological consult.', 'Permanently discontinue study drug/study', 'MYASTHENIA GRAVIS:', 'regimen if Grade 3 imAE does not resolve', 'Steroids may be successfully used to treat myasthenia gravis.', 'to Grade 1 within 30 days or if there are', 'They should typically be administered in a monitored setting', 'signs of respiratory insufficiency or', 'under supervision of a consulting neurologist.', 'autonomic instability.', 'Patients unable to tolerate steroids may be candidates for', 'treatment with plasmapheresis or IV IG.', 'If myasthenia gravis-like neurotoxicity present, consider', 'For Grade 4:', 'starting AChE inhibitor therapy in addition to steroids. Such', 'therapy, if successful, can also serve to reinforce the', 'Permanently discontinue study drug/study', 'diagnosis.', 'regimen.', 'GUILLAIN-BARRE:', 'It is important to consider here that the use of steroids as the', 'primary treatment of Guillain-Barre is not typically', 'considered effective.', 'Patients requiring treatment should be started with IV IG and', 'followed by plasmapheresis if not responsive to IV IG.', 'Myocarditis', 'Any Grade', 'General Guidance', 'For Any Grade:', '-', 'Discontinue drug permanently if biopsy-', 'The prompt diagnosis of immune-mediated myocarditis is important,', 'particularly in patients with baseline cardiopulmonary disease and', 'proven immune-mediated myocarditis.', 'reduced cardiac function.', '-', 'Consider, as necessary, discussing with the study physician.', '-', 'Monitor patients for signs and symptoms of myocarditis (new onset or', 'worsening chest pain, arrhythmia, shortness of breath, peripheral', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 105 de 123']['edema). As some symptoms can overlap with lung toxicities,', 'simultaneously evaluate for and rule out pulmonary toxicity as well as', 'other causes (e.g., pulmonary embolism, congestive heart failure,', 'malignant pericardial effusion). A Cardiology consultation should be', 'obtained early, with prompt assessment of whether and when to', 'complete a cardiac biopsy, including any other diagnostic procedures.', '-', 'Initial work-up should include clinical evaluation, BNP, cardiac', 'enzymes, ECG, echocardiogram (ECHO), monitoring of oxygenation', 'via pulse oximetry (resting and exertion), and additional laboratory', 'work-up as indicated. Spiral CT or cardiac MRI can complement ECHO', 'to assess wall motion abnormalities when needed.', '-', 'Patients should be thoroughly evaluated to rule out any alternative', 'etiology (e.g., disease progression, other medications, or infections)', 'Grade 1', 'No dose modifications required unless', 'For Grade 1 (no definitive findings):', '(asymptomatic with', 'clinical suspicion is high, in which case', '-', 'Monitor and closely follow up in 2 to 4 days for clinical symptoms,', 'hold study drug/study regimen dose', 'BNP, cardiac enzymes, ECG, ECHO, pulse oximetry (resting and', 'laboratory (e.g., BNP)', 'exertion), and laboratory work-up as clinically indicated.', 'or cardiac imaging', 'during diagnostic work-up for other', '-', 'Consider using steroids if clinical suspicion is high.', 'abnormalities)', 'etiologies. If study drug/study regimen is', 'held, resume after complete resolution to', 'Grade 0.', 'Grade 2, 3 or 4', '-', 'If Grade 2 -- Hold study drug/study', 'For Grade 2-4:', 'regimen dose until resolution to', '-', '(Grade 2: Symptoms', 'Monitor symptoms daily, hospitalize.', 'Grade 0. If toxicity rapidly improves to', '-', 'with mild to moderate', 'Promptly start IV methylprednisolone 2 to 4 mg/kg/day or equivalent', 'activity or exertion)', 'Grade 0, then the decision to reinitiate', 'after Cardiology consultation has determined whether and when to', 'complete diagnostic procedures including a cardiac biopsy.', 'study drug/study regimen will be based', '-', 'Supportive care (e.g., oxygen).', '(Grade 3: Severe with', \"upon treating physician's clinical\", '-', 'If no improvement within 3 to 5 days despite IV methylprednisolone at', 'symptoms at rest or', 'judgment and after completion of', '2 to 4 mg/kg/day, promptly start immunosuppressive therapy such as', 'with minimal activity', 'steroid taper. If toxicity does not', 'TNF inhibitors (e.g., infliximab at 5 mg/kg every 2 weeks). Caution: It', 'is important to rule out sepsis and refer to infliximab label for general', 'or', 'exertion;', 'rapidly improve, permanently.', 'guidance before using infliximab.', 'intervention indicated)', 'discontinue study drug/study regimen.', '-', 'Once the patient is improving, gradually taper steroids over >28 days', 'If Grade 3-4, permanently discontinue', 'and consider prophylactic antibiotics, antifungals, or anti-PJP treatment', '(Grade', '4:', 'Life-', '(refer to current NCCN guidelines for treatment of cancer-related', 'study drug/study regimen.', 'threatening', 'infections [Category 2B recommendation]).', 'consequences; urgent', 'intervention indicated', '(e.g., continuous IV', 'therapy or mechanical', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 106 de 123']\n\n###\n\n", "completion": "END"}